About Us
EnoGene Biotech Co. Ltd, is a biological high-tech corporation that specializes in developing and production of antibody related products for biochemistry, molecular biology, immunology and other reagents in general laboratory use. EnoGene Biotech possesses advanced equipments, a highly experienced professional team, and the first class laboratory technology to offer the best products and services to universities, colleges, academes and institutes. At the same time, EnoGene Biotech focuses on transferring and developing the innovative research findings to reagent products. We will contribute to the development of biomedical research with our continuous new products.
At present, we have established the full-blown technology for monoclonal and polyclonal antibodies development. Meanwhile, we provide researchers with biotech services like peptide synthesis, monoclonal antibody development, polyclonal antibody development, antibody validation by Western Blot, ELISA, flowcytometry, immunohistochemistry, etc. Through normative experiment operation, sternly control of the quality, and the full-blown technology, we will provide researchers high-qualified biotech services, saving your time and energy for more secrets in the vast field of life science.
Innovation drives EnoGene continuous growth in the life Science technology field, providing the latest and most advanced services of this domain. In short, we can supply you with constructive suggestions and comprehensive solutions to the problems you meet during antibody development. EnoGene is committed to developing itself to the world's provider of antibodies and antibody related services with the best quality and the most competitive-edge prices. We're sure that EnoGene will become your right hand and a partner you can trust.
EnoGene™,Enjoy Innovation……
Mirabijalone E: A novel rotenoid from Mirabilis himalaica inhibited A5…
타이틀
저자
게시일
게시장소
Abstract
Ethnopharmacological relevance
The roots of Mirabilis himalaica have been used in Tibetan folk medicine for treatment of uterine cancer, nephritis edematous, renal calculus and arthrodynia. In our previous work, the ethanol extract of roots had shown potent cytotoxicity against human cancer cells. However, no information is available on the antitumor effect of Mirabilis himalaica.The aim of the present study was to investigate the active constituents guided by bioassay and evaluate the related antitumor efficacy in vitro and in vivo.
Materials and methods
The active subextract (ethyl acetate) was subjected to successive chemical separation using a combination of silica gel, LH-20 chromatography and semi-preparative HPLC. The structures were determined by spectroscopic analysis techniques such as nuclear magnetic resonance (NMR) and mass spectrometry. Three human cancer cell lines, A549, HepG2 and HeLa were used for in vitro cytotoxicity evaluation of all isolated compounds by MTT-assay. Then, the potent and novel compound mirabijalone E was employed to the mechanism study againstA549 cells. BrdU immunofluorescence, soft agar assay and cell cycle analysis were employed to detect the cell proliferation effects. Annexin V-FITC/PI staining assay was used for examining apoptotic effects. Expression levels of apoptosis-related proteins were determined by western blot assay. in vivotumorigenic assay was used to evaluate the xenograft tumor growth treated with mirabijalone E.
Results
One new rotenoid compound, mirabijalone E, together with eight known rotenoids was isolated from Mirabilis himalaica. Mirabijalone E, 9-O-methyl-inone B, boeravinone C and boeravinone H exhibited cytotoxicity against A 549 and HeLa cells. Further study on mirabijalone E was carried out in vitro and in vivo. Mirabijalone E inhibited A549 cells growth in a time and dose-dependent manner, which arrested cell cycle in S phase. Mechanistically, mirabijalone E treatment resulted in the increase of Bax expression level, the decrease of Bcl-2 level and the activation of caspase-3, which suggested the activation of apoptosis cascades. Consequently, the xenograft treated with mirabijalone E showed markedly suppressed tumor growth.
Conclusions
The result suggested that mirabijalone E, together with active compounds, 9-O-methyl-4-hydroxyboeravinone B, boeravinone C and boeravinone H could be a promising candidate for cancer therapy.
Graphical abstract
Chemical compounds studied in this article
Keywords